| Luo, Chengwei |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
| Zhang, Tao |
NCT05175001: Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain |
|
|
| Recruiting | 4 | 100 | RoW | Diprospan, Compound Betamethasone Injection, Ropivacaine | Affiliated Hospital of Nantong University | Chronic Pain | 06/22 | 01/23 | | |
PIONEER, NCT05029453: Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy |
|
|
| Not yet recruiting | 4 | 60 | RoW | Apatinib | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Randomized Controlled Study | 12/22 | 03/23 | | |
NCT05598177: Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass |
|
|
| Completed | 4 | 64 | RoW | dexmedetomidine, Placebo | Affiliated Hospital of Nantong University | Ischemia-Reperfusion Injury | 05/23 | 12/23 | | |
NCT05922605: Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias |
|
|
| Recruiting | 4 | 44 | RoW | S-ketamine & Ropivacaine, Ropivacaine | Tao Zhang | Postoperative Analgesia, S-ketamine, Pediatrics, Caudal Block, Hypospadias | 04/25 | 05/25 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
NCT03399253: Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor |
|
|
| Recruiting | 3 | 120 | RoW | surgery, chemotherapy, XELOX | Sun Yat-sen University | Gastric Cancer | 11/22 | 12/25 | | |
NCT03399110: XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) |
|
|
| Active, not recruiting | 3 | 1032 | RoW | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Fudan University | Gastric Cancer | 08/26 | 08/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT06753890: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) |
|
|
| Not yet recruiting | 3 | 520 | RoW | Changkang granules, Changkang Granules placebo | Tasly Pharmaceutical Group Co., Ltd | Diarrhea-predominant Irritable Boewl Syndrome | 11/26 | 12/26 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT03135652: Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation |
|
|
| Withdrawn | 2 | 120 | RoW | adjuvant SBRT, radiotherapy, Chemotherapy, neoadjuvant chemotherapy and adjuvant chemotherapy | Wuhan Union Hospital, China | Radiotherapy, Colorectal Cancer, Liver Metastases | 06/21 | 06/23 | | |
MCRC-LC1, NCT03142282: Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 200 | RoW | maintenance chemotherapy, Consolidative Radiotherapy | Wuhan Union Hospital, China | Metastatic Colorectal Cancer, Radiotherapy | 08/21 | 08/24 | | |
NCT04563975: Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Toripalimab, JS001, Docetaxel, Taxotere, nab-paclitaxel, AI YUE | Tao Zhang | Gastric Cancer Stage IV | 12/22 | 05/23 | | |
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric |
|
|
| Not yet recruiting | 2 | 35 | NA | Envafolimab, Endostatin | Wuhan Union Hospital, China | Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy | 07/23 | 12/25 | | |
NCT05202236: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy |
|
|
| Recruiting | 2 | 20 | RoW | pemigatinib | Wuhan Union Hospital, China | Gastric and Colorectal Cancer | 10/23 | 10/24 | | |
UNION PRECISION-I, NCT06234007: Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study |
|
|
| Recruiting | 2 | 45 | RoW | Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine | Wuhan Union Hospital, China, Renmin Hospital of Wuhan University | Locally Advanced Rectal Cancer | 12/24 | 12/27 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06487429: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab | Wuhan Union Hospital, China, RemeGen Co., Ltd. | Gastric Cancer | 05/26 | 05/28 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
AK112-IIT-004, NCT06491472: Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Ivonescimab, AK112/SMT112, Gemcitabine, Nab paclitaxel, SBRT | Wuhan Union Hospital, China, Akesobio | Pancreatic Cancer | 07/26 | 07/27 | | |
NCT06542588: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC |
|
|
| Recruiting | 2 | 29 | RoW | HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody), CAPOX | Wuhan Union Hospital, China | Rectal Cancer | 12/25 | 12/26 | | |
NCT06802666: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 45 | RoW | short-course radiotherapy, SCRT, Ivonescimab, AK112, capecitabine, oxaliplatin, TME surgery | Wuhan Union Hospital, China | Locally Advanced Rectal Cancer, Neoadjuvant Therapy | 09/26 | 12/27 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
NCT05747716: SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC |
|
|
| Not yet recruiting | 2 | 44 | RoW | SBRT, Fruquintinib, Cadonilimab | Wuhan Union Hospital, China | Metastatic Colorectal Cancer | 12/26 | 12/26 | | |
NCT04231552: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 1/2 | 30 | RoW | Camrelizumab, Radiotherapy with CAPOX+ Camrelizumab following surgical therapy | Wuhan Union Hospital, China | Rectal Cancer, Radiotherapy, Immunotherapy | 09/20 | 09/23 | | |
NCT06266143: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 1/2 | 71 | RoW | Y101D | Wuhan YZY Biopharma Co., Ltd. | Advanced Pancreatic Adenocarcinoma | 07/24 | 12/24 | | |
NCT05653180: IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | 1/2 | 20 | RoW | IBI310, sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Biliary Tract Cancer | 12/23 | 06/24 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05747729: A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | Surufatinib and Serplulimab | Wuhan Union Hospital, China | Neuroendocrine Carcinoma | 02/25 | 02/26 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT06144385: A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 20 | RoW | CAR-GPC3 T cells, JWCAR204 | Shanghai Ming Ju Biotechnology Co., Ltd. | Liver Carcinoma, Hepatic Cell Carcinoma | 03/24 | 12/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors |
|
|
| Completed | 1 | 6 | RoW | A:YH002+YH001, B:YH002+YH001, YH002+YH001 | Eucure (Beijing) Biopharma Co., Ltd | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06484556: NW-301 TCR-T in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 9 | RoW | NW-301V, NW-301D | Tao Zhang, Neowise Biotechnology | Tumor, Solid | 06/26 | 06/27 | | |
NCT06437873: Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC |
|
|
| Completed | N/A | 2957 | NA | Total Thyroidectomy (TT), Radioactive iodine treatment(RAIT) | Dezhou Hospital Qilu Hospital of Shandong University | Follicular Thyroid Cancer, SEER Database Analysis | 12/20 | 05/24 | | |
| Completed | N/A | 3068 | NA | Different Pathological Types (FTC vs PTC), Different Pathological Types | Dezhou Hospital Qilu Hospital of Shandong University | Pediatric and Adolescent Differentiated Thyroid Carcinoma, SEER Database Analysis | 12/20 | 08/24 | | |
NCT03426514: Three-port Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 282 | RoW | Three-port Laparoscopic Surgery, Conventional Laparoscopic Surgery | Ruijin Hospital | Colorectal Cancer | 03/20 | 03/25 | | |
NCT05280860: Effect of Bilateral RSB on Postoperative Delirium in Elderly Patients Undergoing Laparoendoscopic Single-site Surgery |
|
|
| Recruiting | N/A | 320 | RoW | ultrasound-guided bilateral rectus sheath block | Affiliated Hospital of Nantong University | Delirium in Old Age, Hernia, Inguinal, Cholecystolithiasis | 12/22 | 12/22 | | |
NCT04360577: Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy |
|
|
| Completed | N/A | 240 | RoW | acupuncture | Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital, Sun Yat-Sen University, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Sixth Affiliated Hospital, Sun Yat-sen University, Southern Medical University, China, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Fifth Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Yuebei People's Hospital | Stomach Neoplasms | 03/23 | 05/23 | | |
NCT05325827: Effect of Ultrasound-guided H-FICB in Patients Undergoing Arthroscopic Knee Surgery |
|
|
| Recruiting | N/A | 44 | RoW | ultrasound-guided high fascia iliaca compartment block | Affiliated Hospital of Nantong University | Knee Disease, Delirium | 12/22 | 02/23 | | |
NCT05533970: Ultrasound-guided H-FICB for Arthroscopic Knee Surgery： What is the Optimal Dose of Dexmedetomidine? |
|
|
| Completed | N/A | 120 | RoW | ultrasound-guided high fascia iliaca compartment block | Affiliated Hospital of Nantong University | Knee Disease, Quality of Recovery | 12/22 | 01/23 | | |
NCT06141421: A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Colorectal Surgeries（SPiM-RWS-CR） |
|
|
| Completed | N/A | 15 | RoW | procedure | Ruijin Hospital | Single-Port Colorectal Surgeries | 08/24 | 08/24 | | |
NCT05820503: Effect of Nerve Block Under Ultrasound on Postoperative Prognosis in Children |
|
|
| Completed | N/A | 112 | RoW | Ultrasound-guided lower abdominis rectus sheath block, Local anesthesia infiltration | Affiliated Hospital of Nantong University | Quality of Recovery | 10/23 | 10/23 | | |
NCT06189183: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection |
|
|
| Recruiting | N/A | 50 | RoW | Adjuvant Hypofractionation Radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Thymus Neoplasms | 12/30 | 12/40 | | |
| Recruiting | N/A | 174 | RoW | Upadacitinib | Xiang Gao | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 12/28 | 12/28 | | |
NCT06508008: Rapid and Safe Sputum Suction Method Validation |
|
|
| Recruiting | N/A | 900 | RoW | continuous negative pressure suction, Intermittent negative pressure sputum suction through oral pharyngeal airway | Affiliated Hospital of Nantong University | Sputum | 07/24 | 08/24 | | |
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage |
|
|
| Not yet recruiting | N/A | 175 | RoW | | Chinese University of Hong Kong | Recurrent Miscarriage | 01/26 | 01/27 | | |
NCT06417749: MIND Diet and Cognitive Function in Middle-aged and Older Adults |
|
|
| Not yet recruiting | N/A | 1200 | RoW | Control arm, Intervention arm | Zhejiang University, Shandong University | Cognitive Function, Dementia | 05/25 | 10/25 | | |
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure |
|
|
| Recruiting | N/A | 720 | RoW | | Chinese University of Hong Kong | IVF | 07/27 | 01/28 | | |
| Coordinator |
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) |
|
|
| Recruiting | 4 | 12 | US | Asceniv™ | ADMA Biologics, Inc. | Primary Immune Deficiency | 03/23 | 06/23 | | |
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies |
|
|
| Recruiting | 3 | 143 | Europe, US | Intervention/Treatment | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/25 | 03/26 | | |
| Recruiting | 3 | 690 | US | Brilaroxazine, RP5063, Placebo | Reviva Pharmaceuticals | Schizophrenia | 02/25 | 02/25 | | |
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 212 | US | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 05/25 | 01/26 | | |
REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 84 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 03/26 | 11/26 | | |
REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 126 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 04/26 | 12/26 | | |
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 3 | 188 | Europe, US, RoW | Veligrotug (VRDN-001), Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease |
|
|
| Recruiting | 2 | 100 | US | Carmustine 7.7Mg Wafer, GLIADEL | University of Nebraska, Arbor Pharmaceuticals, Inc. | Brain Tumor - Metastatic | 12/25 | 12/26 | | |
NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors |
|
|
| Recruiting | 2 | 200 | RoW | YL202 should be intravenously infused | MediLink Therapeutics (Suzhou) Co., Ltd. | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 11/26 | 11/28 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 640 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/27 | | |
| Recruiting | N/A | 2000 | US | | Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health (NIH), University of Chicago, University of Alabama at Birmingham, Rush University, Washington University School of Medicine, Medical University of South Carolina, University Hospitals Cleveland Medical Center, Louisiana State University Health Sciences Center Shreveport, University of Florida, University of Maryland, The University of Texas Health Science Center, Houston, Ochsner Health System | Parkinson Disease | 12/26 | 12/26 | | |
NCT06186596: Self-Administered Intralesional Injections for Acne |
|
|
| Recruiting | N/A | 150 | US | Triamcinolone delivered via injection assistance device | ACOM Labs | Acne Vulgaris | 01/24 | 01/24 | | |
NCT05879198: Train Your Brain: A Pilot Project to Improve Memory and Decision Making |
|
|
| Completed | N/A | 24 | US | Computer-based Intervention | Henry Ford Health System, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Behavior, Health | 09/23 | 09/23 | | |
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD |
|
|
| Recruiting | N/A | 1410 | US | | Aqtual, Inc. | Rheumatoid Arthritis | 06/25 | 12/25 | | |
NCT04642898: Increasing Treatment Efficacy Using SMART Methods for Personalizing Care |
|
|
| Completed | N/A | 66 | US | Standard UP Treatment, Capitalization UP Treatment, Compensation UP Treatment | Shannon E. Sauer-Zavala, National Institute of Mental Health (NIMH) | Anxiety Disorders, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder | 06/24 | 06/24 | | |
NCT03594994: Metabolic Effects of Sleep Extension in People With Obesity |
|
|
| Completed | N/A | 40 | US | Sleep extension | Washington University School of Medicine | Insulin Resistance, Obesity | 07/24 | 07/24 | | |
NCT06242704: Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth |
|
|
| Recruiting | N/A | 72 | US | Working Memory Training, Working Memory | Henry Ford Health System | Behavior, Health | 08/26 | 08/26 | | |
NCT04587518: Five Factor Model Treatment for Borderline Personality Disorder |
|
|
| Completed | N/A | 100 | US | Personality-Based Cognitive Behavioral Therapy | Shannon E. Sauer-Zavala | Borderline Personality Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 03/25 | 03/25 | | |
ELEVATE-HF, NCT06592508: Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 180 | US | Remote Virtual Cardiology Program | Duke University, Ventricle Health | Heart Failure; With Decompensation | 08/26 | 08/26 | | |
NCT03701828: Liver Health and Metabolic Function in People With Obesity |
|
|
| Enrolling by invitation | N/A | 30 | US | Weight loss surgery, Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion | Washington University School of Medicine | Non-Alcoholic Fatty Liver Disease | 11/24 | 03/25 | | |
| Recruiting | N/A | 87 | US | Telemedicine | University of Pennsylvania | Psoriatic Arthritis | 02/25 | 02/25 | | |
| Recruiting | N/A | 200 | Europe | Modified prolonged exposure, Brief intervention, cognitive behavioral therapy | St. Olavs Hospital, Norwegian University of Science and Technology, The Research Council of Norway, Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening), National Centre for Emergency Primary Health Care, NORCE, UiT The Arctic University of Norway | Post Traumatic Stress Disorder, Rape Sexual Assault, Sexual Dysfunctions, Psychological, Pelvic Floor Myalgia, Pelvic Pain Syndrome, Depression, Anxiety, Sleep Disturbance, Activity, Motor, Cortisol Deficiency | 05/25 | 12/27 | | |
| Recruiting | N/A | 506 | US | CHOICES, eBook | University of Florida, National Human Genome Research Institute (NHGRI) | Sickle Cell Disease, Sickle Cell Trait | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 220 | US | EXTEND Plus, EXTEND | Duke University, National Institute of Nursing Research (NINR) | Diabetes Mellitus, Type 2, Hypertension | 10/25 | 10/25 | | |
| Li, Xingya |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05729399: Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 42 | RoW | GT201 | Grit Biotechnology | Solid Tumor | 05/25 | 05/25 | | |
NCT06794957: A Study of AL8326 in Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 158 | RoW | AL8326 tablets, AL8326 | Advenchen Laboratories, LLC | Non-small Cell Lung Cancer | 12/27 | 12/27 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm | 12/24 | 02/25 | | |
NCT05306132: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 |
|
|
| Recruiting | 1 | 150 | RoW | ASKC202 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/24 | 05/25 | | |
